RIPK1 and pulmonary emphysema: Genetic or pharmacological inhibition of RIPK1 using GSK’ 547 markedly lowered airway inflammation following acute and subacute exposure to CS, reduced apoptosis and necrosis induced by chronic exposure, and mitigated airway remodeling and emphysema.